Customer Service: 866-788-9007

How Mohs surgeons Utilize Prognostic Testing for High-Risk Cutaneous Squamous Cell Carcinoma (SCC): A Clinical Impact Study

The study was executed via a clinical impact survey of current American College of Mohs Surgery (ACMS) members with a primary purpose to determine how management of high-risk SCC patients is impacted by use of DecisionDx-SCC.


Study Highlights:


  • A clinical impact survey was distributed to current American College of Mohs Surgery (ACMS) members; a total of 39 members provided responses to a variety of questions, including their familiarity with DecisionDx-SCC and their approach to a number of treatment modalities for a high-risk SCC patient, pre- and post-DecisionDx-SCC test results.
  • 97% of respondents were at least somewhat familiar with or had used the DecisionDx-SCC test.
  • Several National Comprehensive Cancer Network (NCCN) high- or very-high risk factors, such as perineural involvement (PNI), lymphatic or vascular involvement (LVI), poor differentiation and more, that the clinicians believed were the most influential in the development of metastasis were also considered reasons to use DecisionDx-SCC.
  • Additionally, the survey highlighted a risk-appropriate trend where respondents’ overall approach to patient management intensity increased as the DecisionDx-SCC test results indicated an increased risk of metastasis and decreased when test results indicated a lower risk.
  • 42% of Mohs surgeons reported increased confidence in management decisions when DecisionDx-SCC test results were provided.
  • Overall, the study demonstrates how DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions.
  • Additionally, the study suggests that DecisionDx-SCC can focus treatment options in the most risk-appropriate manner, allowing for an optimization of healthcare resources and improved patient outcomes.
Scroll to Top